BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» UCB-0022 is an oral, brain-penetrant compound for PD treatment
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
UCB-0022 is an oral, brain-penetrant compound for PD treatment
Sep. 21, 2022
No Comments
Recent efforts have unveiled UCB-0022 (UCB Pharma Inc.) as an oral, brain-penetrant small molecule acting as a selective D1 positive allosteric modulator.
BioWorld Science
Conferences
Neurology/psychiatric
Small molecule